Site-Dependent Decoupling of Drug-Biomarker Associations in Clear Cell Renal Cell Carcinoma Revealed by Functional Profiling of Patient-Derived Cell Models
Preprint
Abstract
Clear cell renal cell carcinoma (ccRCC) frequently exhibits primary and acquired resistance to standard-of-care therapies, underscoring the need for improved strategies to predict therapeutic response and prioritize patient-specific treatments. Although recent multi-omic and single-cell studies have provided insight into the molecular landscape of ccRCC, molecular alterations alone incompletely predict drug sensitivity. We prospectively profiled tumors from 28 patients with localized and metastatic ccRCC by integrating molecular characterization, functional drug sensitivity and resistance testing in patient-derived cell models, and longitudinal clinical data. Although genomic biomarkers suggested potentially actionable therapies in 27/28 patients, functional testing revealed discordance between genomic actionability and ex vivo drug sensitivity, whereas linear mixed-effects modelling uncovered 16 novel copy-number-based features associated with sensitivity to 11 drugs. Genotype-drug response associations were largely preserved between primary tumors and vena cava thrombi but frequently disrupted in distant metastases. Integrating functional drug testing with multi-omic profiling reveals vulnerabilities not apparent from genomic data alone, refines therapeutic actionability, captures interpatient and intersite heterogeneity in ccRCC, and provides a scalable framework for individualized treatment prioritization.Keywords
Funding Information
- Orionin Tutkimussäätiö
- Munuaissäätiö
- Kymenlaakso Foundation of Finnish Cultural Foundation
- Syöpäjärjestöt
- Syöpäsäätiö
- Governmental research funding Finland
- Finnish Cancer Center FICAN-South
This publication has 44 references indexed in Scilit:
- Exploiting NRF2‐ARE pathway activation in papillary renal cell carcinomaInternational Journal of Cancer, 2024
- Whole genome sequencing refines stratification and therapy of patients with clear cell renal cell carcinomaNature Communications, 2024
- Comparison of two supporting matrices for patient-derived cancer cells in 3D drug sensitivity and resistance testing assay (3D-DSRT)SLAS Discovery, 2023
- Ex Vivo Drug Testing in Patient-derived Papillary Renal Cancer Cells Reveals EGFR and the BCL2 Family as Therapeutic TargetsEuropean Urology Focus, 2023
- Protocol for 3D drug sensitivity and resistance testing of patient-derived cancer cells in 384-well platesSLAS Discovery, 2022
- Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient‐derived cancer cellsInternational Journal of Cancer, 2018
- Genetic and metabolic hallmarks of clear cell renal cell carcinomaBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2018
- Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx RenalCell, 2018
- Hypoxia, Hypoxia-inducible Transcription Factors, and Renal CancerEuropean Urology, 2016
- ROCK Inhibitor and Feeder Cells Induce the Conditional Reprogramming of Epithelial CellsThe American Journal of Pathology, 2012